Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a report released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating on the stock.

A number of other analysts also recently issued reports on DFTX. Robert W. Baird set a $37.00 price target on shares of Definium Therapeutics in a report on Thursday. Jones Trading started coverage on shares of Definium Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price objective for the company. Chardan Capital raised shares of Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Needham & Company LLC restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Finally, Canaccord Genuity Group lifted their price target on Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $35.22.

Definium Therapeutics Stock Down 2.1%

Definium Therapeutics stock opened at $16.88 on Thursday. The business’s 50-day moving average price is $13.76 and its 200 day moving average price is $11.74. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -8.27 and a beta of 2.57. Definium Therapeutics has a 52 week low of $4.70 and a 52 week high of $18.12.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.26). As a group, sell-side analysts anticipate that Definium Therapeutics will post -1.35 earnings per share for the current year.

Insider Activity at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 11,276 shares of the business’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the transaction, the insider directly owned 282,576 shares in the company, valued at $3,715,874.40. The trade was a 3.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Robert Barrow sold 25,791 shares of the stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the completion of the sale, the chief executive officer directly owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 42,667 shares of company stock valued at $561,071. 2.26% of the stock is owned by company insiders.

Institutional Trading of Definium Therapeutics

Several institutional investors have recently made changes to their positions in DFTX. Marshall Wace LLP grew its position in Definium Therapeutics by 31.9% in the second quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after acquiring an additional 828,067 shares during the period. Commodore Capital LP lifted its stake in shares of Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after purchasing an additional 475,000 shares during the last quarter. Orbimed Advisors LLC purchased a new position in shares of Definium Therapeutics during the 3rd quarter worth $4,337,000. Rosalind Advisors Inc. increased its position in shares of Definium Therapeutics by 78.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after purchasing an additional 330,000 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in shares of Definium Therapeutics by 424.9% during the 3rd quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock worth $3,495,000 after purchasing an additional 239,965 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.